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Summary
Objective: Serum levels of procollagen type IIA N-terminal propeptide (sPIIANP) and type-II collagen helical peptide (sHELIXII) biomarkers
were evaluated for variation diurnally and with physical activity and food in participants with osteoarthritis (OA) of the knee.
Methods: Forty participants with OA of at least one knee were admitted overnight to the General Clinical Research Center for serial serum
sampling. Samples were obtained on the evening (6e8 pm) of Day 1 (T3, n¼ 40); prior to rising (8 am) from bed (T0, n¼ 40); 1 h after rising
(9 am) without food consumption (T1a, n¼ 20); 1e2 h after rising (9e10 am) with food consumption (T1, n¼ 40); and additionally at noon, 4 h
after rising (T2, n¼ 20). sPIIANP and sHELIXII were measured by enzyme-linked immunosorbent assay. Results were analyzed using non-
parametric Freidman’s test with Dunn’s post-hoc multiple comparison test.
Results: Normalized mean concentrations for sPIIANP and sHELIXII increased signiﬁcantly from T0 to T1 (P< 0.05).
Conclusions: This is the ﬁrst study to demonstrate diurnal variation of these collagen-II biomarkers in individuals with knee OA. These results
suggest that serum sampling for these markers should be standardized for purposes of clinical trials.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common type of arthritis, the
hallmark of which is cartilage degradation. Human cartilage
matrix is primarily made up of type II collagen, providing
cartilage tensile strength. Changes in type II collagen turn-
over (synthesis and degradation) are believed to play an
important role in the progressive loss of cartilage in OA
and provide biomarkers for the diagnostic and prognostic
evaluation of OA1,2.
Several promising OA biomarkers are derived from type II
collagen, two of which are described herein. Type II colla-
gen is synthesized as a procollagen molecule with both
amino- and carboxy-propeptide domains. Differential splic-
ing produces two forms of the amino-propeptide3, type II
procollagen amino-N propeptides A (PIIANP) and B
(PIIBNP), containing the type IIA and type IIB exons, re-
spectively. Type IIB is expressed in normal adult cartilage.
Type IIA procollagen is expressed by pre-chondrogenic
cells and osteoarthritic-adult chondrocytes, but not normal
adult chondrocytes3,4. Speciﬁc enzymes remove the
amino-propeptides during synthetic processing of type II
collagen, and therefore, serum levels of procollagen type
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1192be representative of the rate of type II collagen synthesis
in the setting of OA. Preliminary studies demonstrate de-
creased sPIIANP in patients with knee OA compared with
healthy controls1, suggesting decreased collagen synthesis
in joint disease.
Collagen degradation occurs via collagenases cleaving
triple-helical region of type II collagen5. Type II collagen he-
lical peptide (HELIXII) is a product of collagen degradation.
Urinary levels of HELIXII have been shown to be signiﬁ-
cantly elevated in OA patients compared to healthy con-
trols5. Recently, a serum HELIXII (sHELIXII) assay has
been developed and found to be more precise than uri-
nary-HELIXII, as urinary levels have limitations from dilution
and creatinine correction6.
sPIIANP and sHELIXII have not been evaluated previ-
ously with respect to important confounding variables,
such as diurnal variation. Other biomarkers that have been
shown to vary diurnally include hyaluronan (HA), matrix met-
alloproteinase-3 (MMP-3), and antigenic keratin sulfate
(AgKS)7e9. HA levels in rheumatoid arthritis (RA) have
been shown to vary signiﬁcantly, especially in early morning
after activity8. Manicourt conﬁrmed these results, and ob-
served that activity after rest caused markers to undergo
predictable changes in RA9. Changes in HA and AgKS
were transient, while in the case of MMP-3, the change per-
sisted for over 3 h. Similar study designs were used to as-
sess diurnal variation of OA biomarkers7,10,11. These
studies were signiﬁcant in clarifying the pathophysiology of
the biomarkers related to disease, and identifying diurnal
variation related to non-disease inﬂuences, demonstrating
1193Osteoarthritis and Cartilage Vol. 16, No. 10that much can be learned from observing biomarker varia-
tion throughout the day. Hence, the aim of this study was
to investigate the variation of sPIIANP and sHELIXII in pa-
tients with OA throughout the day, and more speciﬁcally
with respect to physical activity and food consumption.
Patients and methodsPARTICIPANTSForty patients with knee OA were recruited through the Rheumatology
and Orthopedic outpatient clinics (20 patients for each of two cohorts).
Participants had symptomatic OA of at least one knee. Participants were ex-
cluded for arthritis due to RA, lupus, psoriasis, gout, or hemochromatosis. All
procedures were approved by the Institutional Review Board of Duke Univer-
sity Medical Center (DUMC). Patients were admitted to the General Clinical
Research Center of DUMC for an overnight stay, and standardized meals
were provided. The standardized meals were low in collagen-content, and
food containing hyaline cartilage extracts (i.e., chicken broth, meat gravy,
etc.) were excluded. Participants were allowed to take all usual medications,
including non-steroidal anti-inﬂammatory drugs and dietary supplements
such as glucosamine and/or chondroitin sulfate. Radiographic knee OA se-
verity was assessed from a postero-anterior semi-ﬂexed radiograph with
SynaFlexer positioning device and quantiﬁed by Kellgren Lawrence (KeL)
score for each knee12.BLOOD SAMPLING AND MEASUREMENTSSamples were obtained on all patients between 6:00 and 8:00 pm on Day
1 (T3) after a day of normal activity, and prior to rising from bed (T0). In
cohort-1, samples were collected 1 h after arising, performing morning activ-
ities, and eating breakfast (T1). In cohort-2, this period was parsed into two
intervals: sampling after an hour of morning activity (T1a); and sampling after
breakfast consumption (T1b), corresponding to T1 of cohort-1. For cohort-1,
blood was also obtained 4 h after arising (T2). Analyses of the biomarkers
were performed as previously described by enzyme-linked immunosorbent
assay technique1,5.STATISTICAL ANALYSISThemean concentrations and standard deviations (SDs) of each biomarker
were calculated. Due to strong similar characteristics (see Table I), cohorts
were merged (n¼ 40) for similar timepoints T0, T1, and T3; non-similar time-
points between cohorts (T2 and T1a for ﬁrst and second cohorts, respectively)
were not merged (n¼ 20). Normalized biomarker concentrations were used to
more clearly assess for individual diurnal variation and to remove interpersonal
variation due tomedication and supplement use.Normalization consisted of di-
viding each biomarker concentration by the mean concentration of the four
timepoints for that individual, observing relative-concentration differences
within each patient. The Bland Altman method was used to further assess
whether diurnal variation was dependent on the level of the biomarker13.
Thismethod determineswhether the observed biomarker variation trends sys-
tematically by calculating the difference between T0 and the timepoint with the
greatest variation from T0 and plotting it against the mean of the four time-
points. Results were analyzed using non-parametric Friedman’s test, and
Dunn’s post-hoc multiple comparison test. Statistical computations were per-
formed using JMP (SAS, Cary, NC) and Graphpad softwares. Two-tailed
P-value of less than 0.05 was considered signiﬁcant for all analyses.
Results
Cohort characteristics are described in Table I. The differ-
ence in mean Body Mass Index (BMI) between cohorts wasTable I
Baseline characteristics of the patients in both cohorts
Cohort characteristics Cohort-1 (n¼ 20) Cohort-2 (n¼ 20)
Age Mean (SD) 69 (9) 68 (13)
Median 68 69
Range 55e89 37e97
Gender Male 13 13
Female 7 7
BMI (kg/m2) Mean (SD) 33.76 (10.14) 28.57 (8.34)not statistically signiﬁcant (P¼ 0.09). The sum KeL score
related to both knees ranged from 1 to 8. The distribution
of the sum KeL scores for both knees of the 40 patients
was as follows: 15% had KeL 2, 64% had 3KeL 6,
and 21% had KeL> 6. Three individual knees were scored
as zero due to three patients having undergone unilateral
knee replacement surgery. There was no signiﬁcant corre-
lation between sPIIANP or sHELIXII and sum KeL score.
Nine participants of the 40 enrolled were taking oral glucos-
amine and/or chondroitin sulfate supplements. In addition to
accounting for dietary supplementation through normaliza-
tion, the differences in mean sPIIANP and sHELIXII con-
centrations at T1 (P> 0.50 and P> 0.09, respectively)
and T3 (P> 0.09 and P> 0.50, respectively) between the
supplemented and non-supplemented groups were not sta-
tistically signiﬁcant.
After normalization, there was a mean increase (4.5%) in
sPIIANP between T0 and T1, which was statistically signif-
icant (P¼ 0.036; see Fig. 1). There was also a mean in-
crease (9.0%) in sHELIXII from T0 to T1, which was
statistically signiﬁcant (P¼ 0.038). There was no signiﬁcant
difference in T0 and T3 for either biomarker. sHELIXII also
tended to increase from T0 to T2 (P¼ 0.07), but not from T0
to T1a (P> 0.10). Bland Altman analyses showed that var-
iation was not dependent on the serum level for either
sPIIANP and sHELIXII, and therefore variation did not trend
systematically.
Discussion
Information about diurnal variation of a biomarker has the
potential to improve clinical utility by clarifying whether or
not strict adherence to a standardized time of collection is
necessary to minimize biomarker variation from non-
disease related inﬂuences. Among both cohorts, we ob-
served signiﬁcant diurnal variation in serum concentrations
of PIIANP and HELIXII. Levels of sPIIANP and sHELIXII
rose signiﬁcantly within 1e2 h of initiating morning activities,
which included eating breakfast, however returned to base-
line levels during the day. By analogy to diurnal variation of
HA7,8, we believe this change is from the accumulation of
these biomarkers in the synovium of the OA joint during
rest, and mechanically transported via lymphatics to the cir-
culation during physical activity7. These data suggest that
utility of these biomarkers would beneﬁt from a standardized
collection regimen. Additionally, these ﬁndings are consis-
tent with our previous report of diurnal variation of other
type II collagen biomarkers, speciﬁcally serum type II colla-
gen carboxy-terminal propeptide (sCPII), urinary type II
collagen cleavage neoepitope (uC2C), and type II collagen
C-terminal cross-linked telopeptide (uCTXII)11. In particular,
sCPII, a serum biomarker for collagen synthesis, varied in
a similar pattern, further validating our results.
Mechanistically, it seems plausible to assume that colla-
gen obtained from the diet or dietary supplementation with
the nutracuticals, glucosamine and chondroitin sulfate,
could alter biomarker concentrations in the sera and subse-
quently in the urine. However, limited research has been
done to analyze the effects of diet and dietary supplements
on biomarker levels. The diet provided to participants was
low in collagen and was therefore unlikely to be a con-
founder. Moreover, there are currently no data to suggest
a change in biomarker concentration with dietary supple-
ments. In a 3-year trial of glucosamine for knee OA, there
was no signiﬁcant difference in uCTXII between placebo
and glucosamine-supplemented groups14. In a second trial
studying glucosamine and biomarkers uC1,2C and uC2C
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Fig. 1. Normalized concentrations of sHELIX and sPIIANP vs timepoints. The time of collection and the status (fasting vs non-fasting; at-rest vs
active) is indicated at the top of the ﬁgure for each timepoint. Figure plots represent mean normalized biomarker concentrations 1 SD.
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difference in biomarker levels between placebo and glu-
cosamine-supplemented groups15. Although long-term ef-
fects of glucosamine have been studied, no one has ever
studied its effects on diurnal variation.
This study has limited power to detect small daily variation
in biomarker concentration; however, with a larger sample
size (n¼ 40) for the timepoints T0, T1, and T3, there is a de-
creased likelihood of a type II error (false negative result).
The more limited sample size (n¼ 20) for T1a and T2 may
have limited our power to detect a signiﬁcant difference be-
tween T0 and T2 for sHELIXII. Sample size, along with the
cross-sectional design of the study may have also affected
correlational analysis with the sum KeL score and limited
the power to detect such an association. Although there
was no correlation between these biomarkers and the sum
KeL score, it is nevertheless useful to clearly assess the
severity of knee OA in the sample to determine the applica-
tion of such ﬁndings in the OA population. Furthermore, the
time intervals used may be inadequate for determining
maximal variation. The half-life of biomarker clearance
upon rising may be shorter than these time intervals, requir-
ing more frequent sampling to determine the overall kinetics
of diurnal variation. In this study, each patient served as their
own control. Although a normal healthy reference population
was not included we do not view this as a limitation since OA
trials in which these biomarkers would be applied, would
include only a disease cohort.
Even so, while these limitations may present biases in
our study, this is the ﬁrst study to evaluate diurnal variationof sPIIANP and sHELIXII and provides important informa-
tion for clinical trial design, namely that standardized time
of sampling would be important for these two markers
to minimize variation on the basis of diurnal variation as
opposed to disease related variation.Conﬂict of interest
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